A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors | NYU Langone Health

Go Back to All Clinical Trials

A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-melanoma Skin Cancers
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) > and equal to 1 Cutaneous, subcutaneous, or nodal lesion suitable for Intralesional injection 2) 1 lesion or aggregate > and equal to 10 mm diameter 3) Willing to undergo serial biopsies

You may not be eligible for this study if the following are true:

1) Active herpes infection and autoimmune diseases 2) Solid organ and stem cell transplants